Merck has extended its all-important lung-cancer lead, after combination Phase III trial demonstrates that Keytruda extends lung cancer survival.
Browsing: lung cancer
Discover whether radiotherapy may have a promising role in synergistically enhancing the systemic response to immune checkpoint inhibition in this editorial from Future Oncology.
Recent results from Roche’s Phase III IMpower 150 lung cancer study have demonstrated that atezolizumab, bevacizumab, chemotherapy combination doubles 12-month PFS.
The EU Position Statement on Lung Cancer Screening (EUPS) has presented evidence to address successful implementation of lung cancer screening programs for European countries.
Would you like to find out the key facts about non-small-cell lung cancer? We have…
Three single-nucleotide polymorphisms have been identified as viable candidates as biomarkers for the personalized monitoring and treatment of lung cancers.
Over the coming weeks on Oncology Central we will be highlighting the latest advancements in lung cancer. Join us as we look explore key issues and current understanding in the diagnosis, staging and treatment of the disease by exploring all our content below.
What is the potential clinical significance of the results of the FLAURA trial presented at ESMO? Find out in our exclusive interview.
Listen to this podcast to discover more about CheckMate-153 study, data from which was presented at this years 2017 ESMO Congress (8–12th September, Madrid, Spain).
A recent clinical trial presents new data indicating durvalumab improves progression-free survival in patients with stage III non-small-cell lung cancer (NSCLC).